cs.CLAug 31, 2026

Quantitative Evidence Mining for Plausibility-Aware Biomedical AI: A Narrative Review and Conceptual Framework

Authors: Negin Sadat Babaiha, Stefan Geissler, Marie-Christine Simon, Martin Hofmann-Apitius, Marc Jacobs

Organizations: Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, Germany · Kairntech SAS, 29 Chemin du Vieux Chêne, Meylan 38240, France · Bonn-Aachen International Center for Information Technology (b-it), University of Bonn, Bonn, Germany

Abstract

Biomedical artificial intelligence is moving from literature retrieval toward evidence synthesis for knowledge graphs, clinical decision support, and computational models. Yet most information-extraction systems still represent findings as simple relations, discarding the quantitative and contextual detail needed for interpretation and reuse. A claim that one entity affects another is insufficient when the magnitude, unit, population, comparator, experimental conditions, uncertainty, and provenance are missing. We define quantitative evidence mining as a framework for transforming biomedical findings into structured, context-rich, and auditable evidence units. We define the core elements of an evidence unit: the claim; measured entity and property; value, unit, or scale; comparator; population; biological or clinical conditions; temporal context; uncertainty; provenance; validation results; and expert-review status. We propose an eight-stage reference architecture spanning corpus selection, entity recognition, quantity extraction, context linking, normalization, evidence-unit assembly, multidimensional plausibility assessment, and export and governance. A central principle is that plausibility should not be collapsed into a single truth label; statistical, biological, methodological, contextual, and provenance-based support should remain explicit. The framework links information extraction to evidence synthesis and computational reuse, with applications in clinical-trial analysis, biomarker research, pharmacovigilance, knowledge-graph construction, and mechanistic modelling. It is a research agenda rather than a validated end-to-end system. Progress will require annotated multimodal benchmarks, rigorous component- and workflow-level evaluation, prospective testing, transparent provenance, and sustained expert oversight.

Explore similar work

CardsList